Lokar

Quick links to important sections

Lokar

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lokar

What is Lokar?

Lokar is a medication primarily used in the management of high blood pressure, a condition also known as hypertension. It belongs to a class of drugs called angiotensin II receptor blockers (ARBs). By affecting specific pathways in the body, Lokar helps to manage blood pressure levels and is often utilized to support cardiovascular health.

How It Works

The active mechanism of Lokar involves blocking the action of angiotensin II, a naturally occurring substance in the body that causes blood vessels to tighten and narrow. When these vessels are constricted, the heart must work harder to pump blood, leading to increased blood pressure. By preventing angiotensin II from binding to its receptors, Lokar allows the blood vessels to relax and widen. This process facilitates smoother blood flow and reduces the overall pressure within the circulatory system.

Primary Uses

Lokar is most commonly prescribed for the following purposes:

  • Hypertension Management: Lowering high blood pressure to help reduce the risk of long-term complications such as stroke or heart attack.
  • Kidney Protection: In certain individuals, particularly those with type 2 diabetes and a history of hypertension, it may be used to help protect kidney function over time.
  • Heart Failure Support: It is sometimes used as part of a broader management plan for patients whose hearts do not pump blood as efficiently as they should.

General Characteristics

As an angiotensin II receptor blocker, Lokar is typically favored for its specific targeting of the renin-angiotensin-aldosterone system (RAAS). Unlike some other types of blood pressure medications, it works further down the chemical signaling chain, which can influence how the body handles fluid balance and vascular resistance without affecting other unrelated physiological processes.

What side effects are possible with Lokar?

Possible Side Effects and Safety Information

Lokar, containing the Bisphosphonate Alendronic Acid, has an officially documented safety profile characterized by adverse reactions that are classified by frequency and affected physiological system, as specified in regulatory prescribing information.

Documented Adverse Reactions by System-Organ Class

The most commonly reported adverse events are concentrated in the musculoskeletal and gastrointestinal systems.

System Organ Class Classification Examples
Musculoskeletal Musculoskeletal pain (bone, joint, or muscle), often classified as Very Common (ge 1/10).
Gastrointestinal Abdominal pain, dyspepsia, acid regurgitation, flatulence, and constipation are typically Common (ge 1/100 to < 1/10).

Serious and Exposure-Related Safety Patterns

The regulatory label documents Rare (ge 1/10,000 to < 1/1,000) but serious adverse reactions, including upper gastrointestinal adverse events such as esophageal ulcers and perforation. Other rare but clinically significant skeletal effects include Osteonecrosis of the Jaw (ONJ) and atypical subtrochanteric and diaphyseal femoral fractures, with the latter primarily reported in patients receiving long-term therapy. Transient symptoms as in an acute-phase response (e.g., myalgia, fever) may occur, typically associated with initiation of treatment.

Population-Specific Constraints

The medicine is not recommended for patients with severe renal impairment (creatinine clearance less than 35 mL/min) due to a lack of clinical experience. Furthermore, Alendronic Acid is contraindicated in the presence of uncorrected hypocalcaemia and specific abnormalities of the oesophagus that delay emptying.

Overdose and Emergency Response

Overdose and when to seek help

Overdose from oral administration of Alendronic Acid (Lokar) is officially documented by regulatory authorities to result in two primary clinical categories: acute upper gastrointestinal (GI) irritation and systemic mineral imbalance.

Documented manifestations of overexposure include severe GI effects such as oesophagitis, gastritis, and ulcers. Systemic effects include significant decreases in blood calcium and phosphate levels, known as hypocalcaemia and hypophosphataemia.


When Urgent Medical Help is Required

Regulators explicitly mandate that patients seek medical attention immediately and discontinue the medication if any symptoms suggestive of serious oesophageal reaction appear. These symptoms include dysphagia (difficulty swallowing), odynophagia (pain when swallowing), retrosternal pain (chest pain), or new or worsening heartburn.

Overdose Outcome Severity Classification
Oesophageal adverse experiences Severe, may require hospitalization
Hypocalcaemia/Hypophosphataemia Acute mineral depletion

In case of documented overdosage, administration of milk or antacids may be utilized to bind the drug and limit absorption, though no specific antidote is known according to regulatory prescribing information. Treatment remains focused on symptomatic and supportive management, with necessary monitoring of serum calcium and phosphate levels.

Therapeutic Uses of Lokar

What Lokar treats: main uses and benefits

Easing Distressing Allergy Symptoms and Hay Fever

Lokar may be part of symptomatic management for conditions involving episodic or fluctuating manifestations, such as allergic rhinitis (hay fever) and perennial allergies. It is relevant for managing symptom clusters that may become intense or disruptive, including persistent sneezing, runny nose, nasal congestion, and itchy, watery eyes. This is commonly used when short-term symptomatic assistance is needed.

Supportive Management for Allergy-Related Breathing Discomfort

The medication is also applied when symptoms related to heightened physiological activity and localized discomfort, associated with the allergic component of asthma, require additional support. The medication is applied across therapeutic domains relevant for easing symptoms of allergic rhinitis and supportive management of allergic asthma manifestations. It contributes to a sense of stability during phases of increased distress.

Reducing the Overall Symptom Burden

It is applied in addressing situations involving certain distressing symptoms and may assist with easing the overall symptom load. This means it helps patients cope more steadily with symptom fluctuations, particularly when symptoms interfere with daily comfort.


Quick Fact: Relief for Persistent Sneezing and Congestion

Regulatory References

  1. comprehensive overview of combination therapy for allergic disease

Eligibility and Restrictions for Use

Official Eligibility Rules for Lokar

The eligibility profile for Lokar (sodium zirconium cyclosilicate) is defined by official regulatory documents, primarily restricting use based on age and specific gastrointestinal conditions. This information describes who may use the medicine and who should avoid it.

Population Status Regulatory Classification
Populations for whom use is allowed Adults (18 years and older) who do not have specific contraindications.
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or any of its components.
Populations for whom use is not recommended Patients with severe constipation, bowel obstruction, or bowel impaction, as the drug has not been studied in these conditions and may worsen them.

Age-Based Eligibility:

Use of Lokar is generally restricted to adults. The official label explicitly states that safety and effectiveness have not been established in pediatric patients.

Special Considerations:

  • Pregnancy and Lactation: Because the drug is not absorbed systemically following oral administration, maternal use is not expected to result in fetal or infant exposure.
  • Fluid Overload Risk: Patients with conditions that predispose to fluid overload, such as heart failure or severe kidney disease, should be monitored closely due to the sodium content of the medicine.

The regulatory profile establishes that approved use is confined to adults and mandates caution or avoidance in individuals with pre-existing severe gastrointestinal motility issues, based on the documented risks.

What should I know about interactions with other medicines?

Lokar Interactions with Other Medicines and Products

The following is a summary of documented interaction patterns for Lokar (Alendronic Acid), based strictly on official prescribing information from government regulatory bodies.

Interaction Type Interacting Agents / Classes Regulatory Finding
Absorption Interference Oral medications, Antacids, Calcium supplements, Vitamins, All Food/Beverages These substances are documented to bind with Lokar, resulting in a severe reduction in oral absorption (bioavailability).
Pharmacodynamic Risk Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Aspirin Co-administration is a regulatory precaution due to the potential for an additive risk of upper gastrointestinal irritation or adverse events.
Exposure Alteration Intravenous Ranitidine Documented to increase the systemic bioavailability of oral Lokar; the clinical significance is noted in the label as unknown.

Interaction-Related Restrictions and Timing Rules

Lokar's regulatory profile is strongly focused on preventing absorption failure, leading to mandatory time-based constraints:

  • Mandatory Separation: A minimum waiting period of 30 minutes is required between taking Lokar (with plain water only) and the subsequent intake of all food, beverages (including coffee, juice, and mineral water), antacids, calcium supplements, or any other oral medicinal product.
  • Metabolic Status: Official regulatory documents state that the drug is not metabolized in humans, meaning it does not participate in CYP-enzyme-mediated drug interactions.

The regulatory interaction structure is defined by its highly sensitive absorption profile, requiring strict procedural separation from other oral intake, and includes a specific precaution regarding additive risk with certain analgesics.

Mechanism of Action

How Lokar Works: Mechanism of Action (Alendronic Acid)


High-Affinity Binding and Osteoclast Targeting

The mechanism begins with Alendronic Acid rapidly binding to the hydroxyapatite mineral surface of bone, acting as a depot at sites of active remodeling. This targeted, physicochemical affinity results in the drug being concentrated, and released only when the bone-resorbing cell—the osteoclast—internalizes it via endocytosis, which then facilitates the molecular action.


Molecular Inhibition of the Mevalonate Pathway

Once inside the osteoclast, the drug functions as an inhibitor of the key enzyme, Farnesyl Diphosphate Synthase (FDPS), thereby blocking the mevalonate pathway. This molecular blockade prevents the necessary prenylation (activation) of Small GTPase signaling proteins, which are essential for the cell's structural integrity and function.


Antiresorptive Cascade and Bone Remodeling

The functional inactivation of Small GTPases leads to the rapid disassembly of the osteoclast's cytoskeleton and its inability to attach to the bone surface to resorb bone. This cellular disruption culminates in osteoclast apoptosis (programmed cell death), which results in the suppression of the rate of bone degradation, shifting the physiological balance such that bone formation exceeds bone resorption.

Dosage and Administration Information

Administration Guidelines

The general principles for using Lokar (Alendronic Acid) follow specific procedural requirements, as the medication is administered exclusively via the oral route in tablet, effervescent tablet, or oral solution forms.

Standard Dosing Schedules

Treatment regimens are standardized and depend on the condition being addressed. For the treatment of osteoporosis in adults, the typical dosing pattern is either 70 mg once weekly or 10 mg once daily. For the specialized 6-month course for Paget's Disease of Bone, the standard regimen is 40 mg once daily.

Required Administration Conditions

Proper usage requires adherence to timing and posture rules. Lokar must be taken upon arising for the day with a full glass of plain tap water (not juice or coffee). Ingestion must occur at least 30 minutes before any food, drink, or other medicine to ensure proper absorption. Furthermore, patients must remain fully upright—sitting or standing—for at least 30 minutes after taking the dose. Oral tablets must be swallowed whole and not chewed or crushed.

Population Rules and Duration

Dosage is generally not adjusted for older adults. However, the medicine is not recommended for use in patients with severe kidney impairment (creatinine clearance less than or equal to 35 mL/min). While therapy is often long-term, guidelines recommend that the need for continued treatment be periodically re-evaluated.

Recent Clinical Evidence

Research evidence / Overview of studies for Lokar

Lokar (Alendronic Acid) has been evaluated in extensive, multi-year clinical research, primarily through large, international randomized controlled trials (RCTs). This overview summarizes what official research has explored and reported according to authoritative sources, without providing individual medical advice or interpreting individual patient suitability.


Evidence for Use in Postmenopausal Osteoporosis

Research into the use of Lokar for postmenopausal osteoporosis was studied for its role through large-scale, placebo-controlled trials. These studies specifically examined outcomes related to fracture incidence, including hip, clinical vertebral (spine), and non-vertebral fractures, as well as changes in Bone Mineral Density (BMD) at the hip and spine. The findings describe patterns where treated populations showed measurements of increased BMD at key skeletal sites compared to baseline and placebo groups. The evidence supporting these primary outcomes is rated as High.

However, the certainty of the findings remains low for some outcomes, such as wrist fractures. Research indicates that evidence exploring outcomes related to fracture incidence is less clearly characterized for postmenopausal women who are at a lower initial risk.


Evidence for Use in Male Osteoporosis and Glucocorticoid-Induced Osteoporosis

Lokar was studied for use in men with osteoporosis and was evaluated in men and women receiving long-term glucocorticoid (steroid) therapy, a situation associated with rapid bone density change. These studies explored short-term changes in Bone Mineral Density (BMD) at the lumbar spine and hip over a period of one to two years. Research describes measured changes in BMD at the lumbar spine and documentation of differences in new vertebral fracture incidence compared to placebo in the glucocorticoid-treated groups.


Consistency and Gaps in the Research Landscape

Long-term open-label extension studies explored the durability of the observed measurements, with research describing patterns related to BMD measurements during a decade of continuous treatment. Overall, regulatory and scientific reviews describe a body of evidence where data show patterns related to BMD measurements and fracture incidence in high-risk postmenopausal women over the intermediate term. However, evidence is limited for outcomes in certain patient subgroups and provides limited insight into outcomes reflecting daily functioning or activity level.

Frequently Asked Questions (FAQ)

Common questions about Lokar (FAQ)


Q: Is Lokar available over the counter?

Lokar is classified by regulatory documents as a prescription-only medication containing Alendronic Acid. This means it is not available for purchase over the counter and must be prescribed by a healthcare professional.


Q: How long can a person safely take Lokar?

The official product information indicates that the optimal duration of Lokar treatment has not been definitively established. The need for continued therapy is described as requiring periodic re-evaluation by a healthcare provider, especially after five or more years of use.


Q: Does Lokar interact with birth control pills?

Regulatory information requires Lokar to be taken at least 30 minutes before any other oral medication to avoid a severe reduction in its absorption. Oral contraceptives, like any other oral medicinal product, must therefore have time separation, which is described as mandatory in the official directions.


Q: Is it common to feel tired after starting Lokar?

Some patients may experience a transient acute-phase response shortly after starting treatment. This is described in official documents as a temporary reaction that can include generalized symptoms such as a feeling of being unwell (malaise) or fever, but specific mention of tiredness or fatigue is not consistently listed as an officially reported effect.


Q: Does the effectiveness of Lokar change over time?

Clinical research has explored the long-term durability of the medication's effect. Official studies have examined bone mineral density measurements over many years of continuous treatment to understand the patterns of the drug’s long-term effectiveness.


Q: Is it normal to have mild headaches when first starting Lokar?

Headache is listed in the official safety information as a possible side effect that may occur with Lokar use. This has been reported in clinical experience.


Q: What should I tell my dentist before a procedure if I'm taking Lokar?

Due to the rare, but serious, documented risk of osteonecrosis of the jaw (ONJ), patients who are taking a bisphosphonate are advised in official documentation to inform their dentist before undergoing certain procedures.


Q: Are there specific symptoms that require immediate medical attention while taking Lokar?

Official product information lists specific symptoms that suggest a need for immediate medical review. These include developing chest pain, pain or difficulty swallowing, or new or worsening heartburn, which can be signs of serious problems with the esophagus. In these situations, discontinuation of the medicine and immediate medical review are advised.


Q: What is the difference between the standard and extended-release forms of Lokar?

Lokar is manufactured in several forms, including the standard oral tablet, an effervescent (fizzing) tablet, and an oral solution. Official labels outline specific administration methods for each form to ensure proper absorption by the body.


Q: Do I need to change my diet while using Lokar?

A person does not need to change their long-term diet, but strict adherence to timing rules is essential. Regulatory information requires a mandatory 30-minute separation between taking Lokar (with plain water only) and consuming all food, beverages, calcium supplements, and vitamins to prevent absorption failure.


Q: What should I do if I miss a dose of Lokar?

For the once-weekly dosing regimen, regulatory instructions state the missed tablet should be taken on the morning after it is remembered. However, the instructions emphasize that two tablets must not be taken on the same day, and the person should return to their original chosen weekly schedule afterward.


Q: What happens if I stop taking Lokar suddenly?

The mechanism of action results in a residual anti-resorptive effect that remains in the bone for some time after the medicine is discontinued. Official product information notes this persistent activity, but it does not detail the specific consequences of sudden, unadvised cessation of therapy.


Q: Why is Lokar sometimes called [Name of different drug or chemical compound]?

Lokar is the brand name used for the product. The active chemical ingredient is Alendronic Acid, which may also be referred to by its full chemical name, Alendronate Sodium.


Q: Is Lokar safe for women who are breastfeeding?

According to official safety information, it is currently unknown whether the active ingredient in Lokar is excreted (passed) into human breast milk. This information is based on the limited data available in regulatory documents.


Q: Does Lokar have a boxed warning?

Official documentation from the U.S. Food and Drug Administration (FDA) indicates that Lokar (Alendronate Sodium) does not carry a Black Box Warning, which is the most stringent safety warning a medicine can receive.


Q: Does Lokar make skin more sensitive to the sun?

Regulatory safety documents mention that a rare side effect has included a sunlight-sensitive rash, or photosensitivity reaction. This indicates that some patients may experience a reaction when exposed to sun.


Q: How quickly is Lokar eliminated from the body?

Following administration, the portion of the drug that is not immediately taken up by the bone is rapidly eliminated in the urine. However, the portion that is incorporated into the bone is estimated to have a terminal half-life of over ten years.


Q: Is Lokar associated with any vision problems?

Yes, rare but serious ocular inflammatory reactions have been reported in official documents. These include conditions such as uveitis, scleritis, and episcleritis, which may indicate a need for prompt ophthalmological assessment.


Q: Does Lokar require regular blood monitoring?

Official regulatory guidance states that low calcium levels (hypocalcemia) must be corrected before treatment is started. Official guidance describes a requirement for monitoring of serum calcium levels and symptoms during therapy in patients with conditions that affect mineral metabolism.


Q: Does Lokar cause dizziness?

Dizziness is listed in the official product information as a possible adverse effect that may occur during the use of Lokar.


Q: Can Lokar be taken with alcohol?

While no specific drug interaction with alcohol is reported in the official documents, consumption may potentially increase the risk of certain digestive side effects, such as gastrointestinal irritation. It must also be separated from the medicine by the mandatory 30-minute absorption window required for all beverages.


Q: What happens if a child accidentally takes Lokar?

If a child accidentally takes more than the prescribed amount, regulatory instructions advise that a full glass of milk should be immediately given to help bind the medicine. Contacting a poison control center or seeking emergency medical help right away is advised.


Q: Are there special warnings for people with heart conditions using Lokar?

Although there is no direct heart-specific warning in the main sections, formulations of Lokar contain sodium. Official guidelines suggest that patients with conditions predisposing them to fluid overload, such as severe heart failure, may require closer monitoring due to this sodium content.

How should Lokar be stored and disposed of?

How to Store and Dispose of Lokar?

Storage and disposal instructions for Lokar (Alendronic Acid) are strictly defined by regulatory documents to maintain product stability and ensure safety.


Storage Conditions

Lokar must be stored at controlled room temperature, specifically between 20°C to 25°C (68°F to 77°F), with permitted temperature excursions up to 30 C. To protect the moisture-sensitive tablets, they must remain in the original container or sealed blister packaging and should not be removed until the day of administration. The medication must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Lokar should not be disposed of via wastewater or household trash. Disposal must be conducted according to local pharmaceutical waste regulations, typically by returning the product to a pharmacist or a recognized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lokar found in:

A-Z Index: